Contents
South Dakota fosters a culture of pioneering research through state-of-the-art clinical trials. Experts are dedicated to progressing treatments and improving evidence-based care.
We believe in the power of individuals to contribute to medical progress. Our platform connects you to clinical trials that can shape the future of medicine.
Clinical Trials For Disease Areas in South Dakota
Through community-based clinical research trials, South Dakota experts seek to improve science and meet the needs of every patient. Research facilities study many different diseases. With a strong interest in conditions like cancer, diabetes, heart disease, and brain disease.
One such example is the Sanford Project. It’s a key effort by Sanford Health and is dedicated to discovering a cure for type 1 diabetes. This initiative began with a $400 million donation from philanthropist Denny Sanford in 2007. In 2018, the clinical trial reached a new milestone. It showed that new ways of monitoring insulin doses and glucose levels are on their way.
If you want to apply and volunteer for clinical trials in South Dakota, then you are in the right place. Browse the list below to find out more.
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiographic findings, physical exam, surgical findings, and the repair. Patients will wear a sling post-operatively, and follow standardized rehabilitation protocols, including physical therapy.
Patients will be sent outcome questionnaires at 2, 6, 10, and 20 years after surgery. Read Less
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: Orthopedic Institute, Sioux Falls, South Dakota
Orthopedic Institute, Sioux Falls, South Dakota
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota +2 locations
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Avera Cancer Institute, Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota +1 locations
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
Recruiting
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Sanford Cancer Center, Sioux Falls, South Dakota
Sanford Cancer Center, Sioux Falls, South Dakota
Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastasis From Malignant Melanoma of Skin (Disorder), Metastasis From Malignant Tumor of Bladder (Disorder), Metastasis From Malignant Tumor of Liver, Metastatic Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC
BlueWind RENOVA iStim™ System for the Treatment of OAB
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder. Read Less
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Sanford Health, Sioux Falls, South Dakota
Sanford Health, Sioux Falls, South Dakota
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT (Arm 2). The BAT administered will be determined by the treating physician, with the option to "cross-over" to KRT-232 treatment after 6 months of BAT or if the disease worsens at any time. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Rapid City Regional Hospital, Rapid City, South Dakota +2 locations
Rapid City Regional Hospital, Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Rapid City Regional Hospital, Rapid City, South Dakota +2 locations
Rapid City Regional Hospital, Rapid City, South Dakota
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
Conditions: Previously Treated Non-Small Cell Lung Cancer
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota +1 locations
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
Conditions: Cutaneous Melanoma, Stage II
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Paid Clinical Trials in South Dakota
We understand that your time is valuable. By joining paid clinical trials, you don’t just get access to cutting-edge treatments. But, you also play a role in advancing medical science. With SD paid clinical trials, you receive financial compensation. Or you can get compensated in the form of vouchers, paid travel expenses, and free medical care.
Clinical Trials For Health Volunteers in South Dakota
When you volunteer for a clinical trial, you can learn more about your condition or disease. You can take an active role in your health and try novel therapies that might alleviate the symptoms.
Research teams in South Dakota are constantly looking for health volunteers who can make scientific advances possible. Want to apply? Explore a wide range of trials available near you.
No trials could be found at this time
Medical Discoveries and Innovation in South Dakota
While South Dakota may not have an extensive history of medical innovations as some other states, ongoing research and collaborative efforts within the healthcare community have improved medicine and patient care. Here are some of these improvements:
- Brain research and innovation: The Center for Brain and Behavior Research (CBBRe) has had a significant impact on clinical research. Especially in the fields of neurology and neuroscience. Their studies helped improve early intervention, diagnosis, and treatment approaches.
- Infectious disease research: South Dakota research institutions actively collect, analyze, and interpret health data to monitor infectious diseases. Their data helps identify patterns, trends, and therapy impact.
- The 1815 Project: In 2018, the CDC released a call to address health issues among U.S. citizens with heart problems and diabetes through CDC-1815. Facilities in South Dakota worked together to create a 5-year plan to develop possible solutions and find different barriers to patient care.
Why South Dakota Is A Great Place For Clinical Research
For medical trials to advance, diverse data is necessary. South Dakota has a relatively diverse patient demographic. About 80.8% of its residents are White, 8.2% are American Indian, 4.6% are Hispanic, 2.3% are Black, 2.3% are Multiracial, and 1.6% are Asian.